文献速递神经肿瘤

靶向持续性转录干预Myc驱动的髓母细胞瘤调控环路

Targeting processive transcription for Myc-driven circuitry in medulloblastoma.
PubMed 文献 · Neuro Oncol · 2025-01-01

髓母细胞瘤是儿童最常见的恶性脑肿瘤,Myc扩增型(Myc-MB)预后差且直接靶向Myc困难。研究汇总8项CRISPR-Cas9筛选,发现CDK9是Myc-MB的保守依赖点,抑制CDK9可破坏增强子-启动子活性并下调Myc驱动转录程序,与CDK7抑制协同产生强抗肿瘤效应。

要点

  • 8项CRISPR-Cas9筛选鉴定CDK9为Myc-MB的保守依赖点。
  • CDK9抑制与CDK7抑制在Myc-MB细胞中具有协同作用。
  • 抑制转录CDK可破坏Myc-MB增强子-启动子活性并下调Myc驱动程序。

核心结论

  • 研究结果将CDK9抑制确定为治疗Myc-MB具有转化前景的策略。

研究设计与样本

  • 汇总来自3个独立实验室的8项CRISPR-Cas9筛选以鉴定Myc-MB的保守依赖点。
  • 对原发患者Myc-MB样本行染色质构象捕获(Hi-C)以绘制增强子-启动子互作。
  • 在体外及异种移植模型中使用CDK9/7抑制剂评估对Myc驱动程序及肿瘤生长的影响。

主要发现

  • 8项CRISPR-Cas9筛选鉴定CDK9为Myc-MB的保守依赖点。
  • Myc-MB细胞对CDK9抑制敏感,且与同时抑制CDK7具有协同作用。
  • 抑制转录CDK破坏Myc-MB的增强子-启动子活性并下调Myc驱动转录程序,产生强效抗肿瘤作用。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medulloblastoma is the most common malignant brain tumor of childhood. The highest-risk tumors are driven by recurrent Myc amplifications (Myc-MB) and experience poorer outcomes despite intensive multimodal therapy. The Myc transcription factor defines core regulatory circuitry for these tumors and acts to broadly amplify downstream pro-survival transcriptional programs. Therapeutic targeting of Myc directly has proven elusive, but inhibiting transcriptional cofactors may present an indirect means of drugging the oncogenic transcriptional circuitry sustaining Myc-MB. METHODS: Independent CRISPR-Cas9 screens were pooled to identify conserved dependencies in Myc-MB. We performed chromatin conformation capture (Hi-C) from primary patient Myc-MB samples to map enhancer-promoter interactions. We then treated in vitro and xenograft models with CDK9/7 inhibitors to evaluate the effect on Myc-driven programs and tumor growth. RESULTS: Eight CRISPR-Cas9 screens performed across 3 independent labs identify CDK9 as a conserved dependency in Myc-MB. Myc-MB cells are susceptible to CDK9 inhibition, which is synergistic with concurrent inhibition of CDK7. Inhibition of transcriptional CDKs disrupts enhancer-promoter activity in Myc-MB and downregulates Myc-driven transcriptional programs, exerting a potent antitumor effect. CONCLUSIONS: Our findings identify CDK9 inhibition as a translationally promising strategy for the treatment of Myc-MB.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Sobral LM, Walker FM, Madhavan K, et al. Targeting processive transcription for Myc-driven circuitry in medulloblastoma. Neuro Oncol. 2025. PMID: 40372972. doi:10.1093/neuonc/noaf121

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。